Published in Am J Psychiatry on October 01, 1994
Rethinking schizophrenia. Nature (2010) 4.85
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull (2007) 3.24
Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull (2005) 2.20
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med (2014) 1.73
Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr Bull (2006) 1.67
Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull (2009) 1.54
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull (2009) 1.52
A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull (2012) 1.43
Schizophrenia. J Neurol Neurosurg Psychiatry (1996) 1.43
Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res (2008) 1.41
Recovery and severe mental illness: description and analysis. Can J Psychiatry (2014) 1.37
Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry (2010) 1.36
Neurocognition: clinical and functional outcomes in schizophrenia. Can J Psychiatry (2014) 1.32
The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology (2007) 1.31
Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) (2003) 1.27
Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull (2007) 1.26
A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry (2012) 1.25
Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. World Psychiatry (2004) 1.14
Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat (2006) 1.11
Clinical recovery in first-episode psychosis. Schizophr Bull (2008) 1.11
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology (Berl) (2006) 1.07
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol (2008) 1.06
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) (2003) 1.06
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
Rationale for the study of early intervention. Schizophr Res (2001) 1.01
Neural correlates of cognitive improvements following cognitive remediation in schizophrenia: a systematic review of randomized trials. Socioaffect Neurosci Psychol (2016) 1.00
Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull (2013) 1.00
Fostering Recovery from Life-Transforming Mental Health Disorders: A Synthesis and Model. Soc Theory Health (2004) 0.99
The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci (2010) 0.98
The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res (1998) 0.97
Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr Bull (2007) 0.96
Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull (2006) 0.96
Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm (Vienna) (2006) 0.96
Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community. Indian J Psychiatry (2010) 0.94
Improving outcome in schizophrenia: the case for early intervention. CMAJ (1999) 0.94
Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. Eur Arch Psychiatry Clin Neurosci (2015) 0.92
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci (2007) 0.92
Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophr Res (2015) 0.92
Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry (2005) 0.91
Cognitive remediation therapy needs funding. Nature (2010) 0.89
New paradigms for treatment development. Schizophr Bull (2007) 0.89
The MATISSE study: a randomised trial of group art therapy for people with schizophrenia. BMC Psychiatry (2010) 0.89
Cognition in schizophrenia: Past, present, and future. Schizophr Res Cogn (2014) 0.88
Technology, society, and mental illness: challenges and opportunities for assessment and treatment. Innov Clin Neurosci (2012) 0.88
Diagnostic change 10 years after a first episode of psychosis. Psychol Med (2015) 0.87
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) (2003) 0.87
Ten-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study. J Nerv Ment Dis (2015) 0.86
Schizophrenia--time to commit to policy change. Schizophr Bull (2014) 0.86
Anosognosia in schizophrenia: hidden in plain sight. Innov Clin Neurosci (2014) 0.84
From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol Sci (2012) 0.84
Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry (2012) 0.84
Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. Psychol Med (2016) 0.84
The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health (2008) 0.83
Hannover study on long-stay hospitalization - part I: prediction of long-stay hospitalisation in cases of chronic mental illness. Clin Pract Epidemiol Ment Health (2006) 0.83
Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. Prim Care Companion J Clin Psychiatry (2000) 0.82
Long term outcome of treating schizophrenia. BMJ (2004) 0.82
Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci (2010) 0.82
Schizophrenia. BMJ Clin Evid (2012) 0.81
Gray matter volume decreases in elderly patients with schizophrenia: a voxel-based morphometry study. Schizophr Bull (2011) 0.81
The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci (2006) 0.81
Strategies for effective recruitment of individuals at risk for developing psychosis. Early Interv Psychiatry (2011) 0.80
Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci (2014) 0.80
Introducing recovery. Can J Psychiatry (2014) 0.80
Mental health service utilization among patients with severe mental disorders. Community Ment Health J (2010) 0.79
Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia. Indian J Psychiatry (2010) 0.79
Insights and treatment options for psychiatric disorders guided by functional MRI. J Clin Invest (2003) 0.79
The recognition and optimal management of early psychosis: an evidence-based reform. World Psychiatry (2002) 0.79
Stability and prediction of schizophrenia from adolescence to adulthood. Eur Child Adolesc Psychiatry (2005) 0.78
Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia. Indian J Psychiatry (2012) 0.78
Quetiapine versus aripiprazole in the management of schizophrenia. Ther Adv Psychopharmacol (2015) 0.78
Awareness and coping with emotion in schizophrenia: acceptability, feasibility and case illustrations. Clin Psychol Psychother (2013) 0.77
Schizophrenia: a 100-year retrospective. Am J Psychiatry (1995) 0.77
A systemic and value-based approach to strategic reform of the mental health system. Health Care Anal (1999) 0.76
Schizophrenia: a 100-year retrospective. Am J Psychiatry (1995) 0.76
Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment. Ment Illn (2012) 0.75
Does Schizophrenia Exist? Med J Armed Forces India (2011) 0.75
The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service. BMC Psychiatry (2015) 0.75
Concept and Management of Treatment Resistant Schizophrenia (TRS). Indian J Psychiatry (2004) 0.75
From neuroleptics to neuroscience and from Pavlov to psychotherapy: more than just the "emperor's new treatments" for mental illnesses? EMBO Mol Med (2016) 0.75
Magnetic resonance imaging DTI-FT study on schizophrenic patients with typical negative first symptoms. Exp Ther Med (2016) 0.75
Issues and developments related to assessing function in serious mental illness. Dialogues Clin Neurosci (2016) 0.75
Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study. Psychiatry Investig (2016) 0.75
Schizophrenia: a 100-year retrospective. Am J Psychiatry (1995) 0.75
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry (2017) 0.75
Schizophrenia (maintenance treatment). BMJ Clin Evid (2009) 0.75
Schizophrenia: a 100-year retrospective. Am J Psychiatry (1995) 0.75
Genetics of Schizophrenia: Ready to Translate? Curr Psychiatry Rep (2017) 0.75
Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med (1987) 7.13
Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry (1999) 5.29
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry (1993) 4.98
Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics (1991) 3.24
Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand (2001) 2.42
False neurotransmitters and hepatic failure. Lancet (1971) 2.34
The Yugoslavia Prospective Lead Study: contributions of prenatal and postnatal lead exposure to early intelligence. Neurotoxicol Teratol (2001) 2.25
Childhood abuse in first-episode psychosis. Br J Psychiatry (1994) 2.17
Side effects and the "blindability" of clinical drug trials. Am J Psychiatry (1992) 2.13
Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry (1989) 2.07
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry (1998) 2.00
Suicidal risks among 2826 Sardinian major affective disorder patients. Acta Psychiatr Scand (2007) 1.87
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol (2001) 1.86
Extent of comorbidity between mental state and personality disorders. J Pers Disord (1997) 1.81
Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand (2008) 1.78
Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry (2000) 1.71
Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain. Int J Dev Neurosci (2000) 1.71
Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry (2000) 1.66
Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull (1988) 1.66
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry (1997) 1.61
Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry (1998) 1.60
The predictive power of diagnostic tests and the effect of prevalence of illness. Arch Gen Psychiatry (1983) 1.60
Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res (2006) 1.57
Unipolar mania reconsidered: evidence from an elderly cohort. Br J Psychiatry (1994) 1.57
Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand (2003) 1.52
Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand (2011) 1.52
Low-level lead exposure, social class, and infant development. Neurotoxicol Teratol (1989) 1.51
Lithium salts: 1970-1975. Ann Intern Med (1975) 1.48
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res (2003) 1.47
Results, charges, and benefits of intensive care for critically ill patients: update 1983. Crit Care Med (1984) 1.46
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry (1994) 1.45
Substance abuse and the chronically mentally ill: a description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J (1995) 1.45
The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry (1999) 1.45
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. Schizophr Res (2000) 1.44
The effect of drugs on the release of norepinephrine-H from central nervous system tissued by electrical stimulation in vitro. J Pharmacol Exp Ther (1967) 1.44
Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry (1980) 1.43
Increasing frequency of the diagnosis of obsessive-compulsive disorder. Am J Psychiatry (1992) 1.43
Zinc salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. J Clin Psychiatry (1994) 1.42
Research reports on treatments for bipolar disorder: preliminary assessment of methodological quality. Acta Psychiatr Scand (2005) 1.41
[The adult form of metachromatic leukodystrophy with a predominantly psychotic manifestation]. Nervenarzt (1988) 1.40
First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry (1998) 1.40
Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry (1993) 1.40
A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry (1993) 1.39
A new identity for misidentification syndromes. Compr Psychiatry (1994) 1.39
[Hemispheric laterality and early childhood autism. A case study of the etiologic and nosologic problem of the autistic syndrome in childhood]. Nervenarzt (1987) 1.39
Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry (1994) 1.39
[Significance of historical and current hallucinogenic research in psychiatry]. Nervenarzt (1993) 1.39
Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry (1995) 1.39
Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry (1988) 1.38
Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord (2000) 1.36
Environmental correlates of infant blood lead levels in Boston. Environ Res (1985) 1.35
Correlates of low-level lead exposure in urban children at 2 years of age. Pediatrics (1986) 1.35
Early sensory-motor development and prenatal exposure to lead. Neurobehav Toxicol Teratol (1985) 1.34
An epidemiological assessment of immunization programme participation in the Philippines. Int J Epidemiol (1985) 1.32
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res (2003) 1.29
The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry (2000) 1.28
MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. Am J Psychiatry (1998) 1.28
Seasonal mood disorders. Patterns of seasonal recurrence in mania and depression. Arch Gen Psychiatry (1993) 1.24
Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry (2001) 1.22
Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry (1998) 1.20
Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry (1975) 1.20
Low-level lead exposure and infant development in the first year. Neurobehav Toxicol Teratol (1986) 1.19
Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry (1997) 1.19
Pharmacologically induced behavioural supersensitivity to apomorphine. Nat New Biol (1973) 1.19
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry (1997) 1.18
Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry (1988) 1.16
Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry (1999) 1.16
Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry (2000) 1.15
Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry (1998) 1.14
Effects of lithium and of pH on synaptosomal metabolism of noradrenaline. Nature (1970) 1.14
Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry (1998) 1.14
Psychological versus pharmacological treatments of bulimia nervosa: predictors and processes of change. J Consult Clin Psychol (1999) 1.14
Postnatal development of dopamine D1-like receptors in rat cortical and striatolimbic brain regions: An autoradiographic study. Dev Neurosci (1999) 1.13
Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry (1998) 1.12
Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand (2009) 1.11
The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry (1985) 1.11
Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psychosom (1995) 1.11
A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry (1989) 1.10
Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology (1973) 1.10
The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res (1996) 1.10
Circadian locomotor activity rhythms in Alzheimer's disease. Neuropsychopharmacology (1991) 1.09
Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi. Neurosci Lett (1998) 1.09
Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry (1999) 1.09
Lead, IQ and social class. Int J Epidemiol (1989) 1.08
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol (2001) 1.08
A sensitive and specific enzymatic isotopic assay for tissue histamine. J Pharmacol Exp Ther (1966) 1.08
Pathogenesis and therapy of hepatic coma. Prog Liver Dis (1976) 1.07
Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry (1988) 1.05
Functional impairment and cognition in bipolar disorder. Psychiatr Q (2000) 1.04
Heuristic models of comorbidity of axis I and axis II disorders. J Pers Disord (1997) 1.03
Postnatal development of dopamine D4-like receptors in rat forebrain regions: comparison with D2-like receptors. Brain Res Dev Brain Res (1998) 1.03
Factors associated with noncompliance with psychiatric outpatient visits. Psychiatr Serv (2001) 1.03
Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry (1991) 1.02
Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience (1998) 1.02